Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPSI-PSO: Secukinumab in Moderate to Severe Psoriasis
NCT02595970Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2015
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of secukinumab in plaque psoriasis, sponsored by Novartis. Started May 2015; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02595970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02595970.